Endologix Launches ALTO Abdominal Stent Graft System in Europe

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

October 15, 2020

Furthering its mission to transform the treatment of aortic disorders, Endologix LLC today announced the first implant of its ALTO™ Abdominal Stent Graft, commencing the European commercial release of the recently CE Mark approved endograft.

“We are pleased to expand the product launch to include Europe, making ALTO available to our physician partners and patients there as well as in the U.S.,” commented Prof. Matt Thompson, chief medical officer of Endologix. “ALTO offers a highly differentiated endovascular treatment option for AAA patients and includes design features that we believe will enhance ease-of-use, improve acute outcomes and preserve the long-term durability associated with patient-specific anatomically adaptive sealing.”

The first case was performed at East & North Hertfordshire Hospital in Stevenage, England, by Mr. Matthew Metcalfe (Consultant Vascular Surgeon) and Dr. Kate Steiner (Consultant Interventional Radiologist). The ALTO device was specifically chosen for this patient because he felt the patient’s short, thrombus-lined conical aortic neck could only be treated using ALTO.

“We are very excited to have access to the ALTO device given its unique approach to excluding the aneurysm using a custom sealing technology, and the higher sealing ring enabled me to land and seal in healthy aortic tissue, which should give this patient a good long-term durable outcome,” Mr. Metcalfe said. “Building off previous product generations, there have been a whole host of feature enhancements which we have been anticipating, such as ALTO’s 7mm neck requirement and 15F delivery system, which allow us to treat a diverse set of patient anatomies.”

The commercial release of ALTO in Europe will be supported by a world-class team of sales representatives, clinical specialists and distributors, all focused on the collective objective of improving the health and lives of patients with aortic disorders through a steadfast commitment to delivering innovative and trusted endovascular aneurysm repair (EVAR) solutions.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.